Identifying outcome measures for clinical trials in juvenile idiopathic arthritis associated uveitis for the MIWGUC proposal: a scoping review to create domains from existing outcome measures Authors: Ilaria Maccora, Giulia Inguscio, Stefano Romano, Ivan Foeldvari, Jordi Antón-Lopez, Gabriele Simonini Published: 2026 ABSTRACT Background and aimsChronic anterior uveitis represents the most important extra-articular manifestation of Juvenile Idiopathic Arthritis (JIA). Previous reviews have shown that outcome measures for this condition are widely heterogeneous. Therefore, our aim was to update the 2019 systematic literature review and to identify similarities, differences, and emerging outcome domains reported over the subsequent five years.MethodsWe performed a systematic literature review from 1st January 2019 to 28th February 2025 to identify studies investigating outcome measures used in JIA-associated uveitis (JIA-U), according to PRISMA guidelines.ResultsWe identified 261 papers, of whom 90 potentially eligible. After the full-text revision, 37 studies plus the previous 27, including 1 randomized clinical trial (RCT), were included. Among these studies, 15 outcome measures for JIA-U were identified. Based on their characteristics, we categorized them into three different subgroups: outcome measures for disease activity (30 studies); outcome measures correlated to structural damage (29 studies); and outcome measures of severe disease course (20 studies). The most frequent outcome measures used were the assessment of anterior chamber (AC) cells (29 studies), the visual acuity (21 studies), the development of structural complications (20 studies) and the use and sparing of immunosuppressive therapies (15 studies). Compared with the 2019 review, we identified four studies reporting novel objective techniques for inflammation assessment, including laser flare photometry and anterior segment optical coherence tomography.ConclusionsOur review confirms the variety of outcome measures for JIA-U while highlighting the emergence of novel imaging and biomarker-based measures. These findings provide an updated evidence base for revising the core outcome set and emphasize the urgent need for a consensus and a composite score, which are essential both for designing endpoints in clinical trials and for guiding treatment choices in clinical practice. Background Anterior uveitis is the most frequent extra-articular complication of Juvenile Idiopathic Arthritis (JIA) and its prevalence ranges between 11.6 and 30% [1]. The risk of developing JIA-associated uveitis (JIA-U) is the highest during the first 12 months from disease onset and the lowest after 4 years. In a minority of cases (2–7%), it can also precede the onset of arthritis [2]. In most patients, JIA-U is a chronic anterior uveitis, although panuveitis can be associated rarely [1]. Its presentation is usually asymptomatic, of note, when uveitis is associated with oligoarticular, psoriatic and rheumatoid factor-negative polyarticular subtypes of JIA [1]. Periodic ophthalmologic examinations are therefore strongly recommended. Potential complications associated with ongoing disease activity, as well as the use of corticosteroid therapy, include glaucoma, cataracts, band keratopathy, posterior synechiae and macular oedema [3]. Considering the potential risk of onset of disabling long-lasting complications, an early diagnosis and an appropriate treatment based on the severity of the uveitis are crucial. During the last years, several studies investigating JIA-U have been conducted and a wide variety of measures of outcomes used, thus hampering the possibility to compare disease course, risk of complications and treatment effect [2]. The systematic review published by Mastrangelo et al. [2] in 2019 represented the first comprehensive effort to catalogue outcome measures used in JIA-U; it identified a cluster of outcome measures used in JIA-U, and suitable to assess disease activity, severity, and damage. Based on those results, the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC), using a Delphi and nominal group technique, proposed a core set of measures of outcome distinguished, then tested in a validation cohort of 82 patients [4]. Since the publication of that review, the field has evolved substantially. Novel biologic therapies have entered clinical practice, prospective studies and randomized clinical trials have become available, and objective technologies for quantifying ocular inflammation have gained increasing attention. Consequently, an updated assessment of the literature is required to determine whether the original framework remains adequate or whether additional domains should be considered. The aim of this study was not only to update the previous systematic review published in 20192, but also to evaluate the temporal evolution of outcome assessment in JIA-U that could better serve as endpoints in clinical trials and drive treatment choices in everyday clinical practice [5]. Methods This study was conceived as an update extension of the systematic review published in 20192. Therefore, identical eligibility criteria were intentionally maintained to allow direct comparison of outcome measures identified before and after publication of the original review. According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) [6], a systematic review from January 1st 2019 up to February 28th 2025 has been conducted to identify the existing published evidence concerning the use or the proposed use of outcome measures in JIA-U. Eligibility criteria The eligibility criteria were: 1) studies focused on JIA-U; 2) data on patients with disease onset at or before age 16 years; 3) to report measures or indicators of the disease history of JIA-U, including risk/prognostic factors and treatment efficacy; 4) to be published in English. The exclusion criteria were: 1) studies focused on adults; 2) studies from which it has not been possible to extract data on children; 3) studies not focused on JIA-U; 4) individual case reports, and 5) conference abstracts. We did not include age limits in the keywords in order to have the possibility to extract data of children from studies including both children and adults. In order to overview and overall scan literature for the current used items regarding JIA-U, any additional selection of potential outcome measure indicators has been used. Any attempt to judge the performance and reliability of each item has been considered into the selection procedure. Information sources Publications were retrieved using a computerized search of the following databases: EMBASE, Ovid MEDLINE, Evidence-Based Medicine (EBM) Reviews—ACP Journal Club, EBM Reviews—Cochrane Central Register of Controlled Trials, EBM Reviews—Cochrane Database of Systematic Reviews and EBM Reviews—Database of Abstracts of Reviews of effects. Publications between January 1st 2019 and February 28th 2025 were included. Search strategy The research was conducted on PubMed and EMBASE with the keywords “chronic uveitis” or “chronic iridocyclitis” or “recurrent uveitis” or “refractory uveitis” or “non-infectious uveitis” or “autoimmune uveitis” crossed with “outcome” or “arthritis”. Initially, we did not include age limits in the search as MeSH terms to have the possibility to extract a sub-cohort of children from studies including both children and adults. No limitation with regard to the type of study was entered. Further, relevant studies captured from the research strategy but focused on adults and/or not including children were excluded. This strategy excluded records related to infectious and/or suppurative uveitis. Study selection Two reviewers (S.R, G.I.) independently screened the retrieved titles and abstracts and excluded duplicates and those obviously irrelevant. If the information in the abstracts was insufficient to decide, full papers were retrieved. Full papers of the selected articles were examined to determine whether they satisfied the criteria (G.I.) and then confirmed by a second reviewer (S.R.). The references of all eligible articles including reviews, expert opinion papers and systematic reviews were manually searched for potentially eligible publications. During consensus meetings (G.I., S.R., I.M, G.S), disagreements of selections were resolved. In addition, we contacted authors of studies to determine whether data on an eligible subgroup were available. Statistical analysis Considering the nature of the collected data in the present systematic review, data have been reported using descriptive statistics, as numbers and proportions. A quantitative comparison analysis has been performed between the results of the previous systematic review [2] and the results of the present. Results The search strategy identified 8254 articles from January 2000 to December 20182, and additional 261 articles from 1st January 2019 up to 28th February 2025. After title and abstract evaluation, 8165 articles in the first research and 171 articles in the current one were excluded mainly due to the absence of an eligible population, non-English language, not sufficiently relevant to the disease focus. Details of the study selection process are provided in the PRISMA Flow diagram (Fig. 1). Full texts of the remaining 89 and 90 studies respectively, were analysed, leading to the selection of a total of 27 and 37 relevant articles, respectively, including three randomized clinical trials (RCTs). Fig. 1Study flow diagram showing the results of the literature search; the first number of papers refers to the research conducted in 2019 (Mastrangelo et al. [2]), the second one to the current research. Abbreviations: n: number of identified studies; JIA-U: juvenile idiopathic arthritis associated uveitis Study flow diagram showing the results of the literature search; the first number of papers refers to the research conducted in 2019 (Mastrangelo et al. [2]), the second one to the current research. Abbreviations: n: number of identified studies; JIA-U: juvenile idiopathic arthritis associated uveitis Comparison with the 2019 review [2] revealed substantial continuity across core outcome measures. Merging the previous and the current results from the 2 systemic reviews, 15 JIA-U outcome measures have been identified: 12 before 2019 and 15 total up to February 2025 (Table 1, Fig. 2). Table 1Outcome measures identified in the review by Mastrangelo et al. [2] and in the current reviewMastrangelo et al. 2Current reviewNumber of included articles2737Total of identified outcome measures1212Grade of cells in the anterior chamber1129Grade of flare in the anterior chamber713Laser flare photometry02Anterior segment optical coherence tomography02Macular oedema07Visual acuity1421Amblyopia10Development of structural complications1720Surgery requirement64Use and sparing of topical/oral corticosteroids1115Biomarkers114Bilateral disease50JIA persistence20Uveitis subtype12Quality of life43Abbreviations: JIA: Juvenile Idiopathic ArthritisFig. 2Venn diagram showing the outcome measures from the literature search: in the left the ones from the previous research conducted in 2019 (Mastrangelo et al. [2]), in the right from the current research and in the center the overlapping outcome measures. Abbreviations: JIA: juvenile idiopathic Arthritis; AC: anterior chamber; AS-OCT: anterior segment optical coherence tomography Table 1Outcome measures identified in the review by Mastrangelo et al. [2] and in the current reviewMastrangelo et al. 2Current reviewNumber of included articles2737Total of identified outcome measures1212Grade of cells in the anterior chamber1129Grade of flare in the anterior chamber713Laser flare photometry02Anterior segment optical coherence tomography02Macular oedema07Visual acuity1421Amblyopia10Development of structural complications1720Surgery requirement64Use and sparing of topical/oral corticosteroids1115Biomarkers114Bilateral disease50JIA persistence20Uveitis subtype12Quality of life43Abbreviations: JIA: Juvenile Idiopathic Arthritis Outcome measures identified in the review by Mastrangelo et al. [2] and in the current review Abbreviations: JIA: Juvenile Idiopathic Arthritis Venn diagram showing the outcome measures from the literature search: in the left the ones from the previous research conducted in 2019 (Mastrangelo et al. [2]), in the right from the current research and in the center the overlapping outcome measures. Abbreviations: JIA: juvenile idiopathic Arthritis; AC: anterior chamber; AS-OCT: anterior segment optical coherence tomography Nine out of 15 outcome measures resulted identical, 3 were described only in the previous review and additional other 3 were retrieved from the current research (Fig. 2). Based on the type of the different identified measures of outcomes, 4 different subgroups of analysis have been considered (Fig. 3): Outcome measures to assess disease activity: Grade of cells in the anterior chamber [7–46];Grade of flare in the anterior chamber [7–18, 27, 36, 38, 39, 42, 43, 47, 48];Laser flare photometry [27, 33, 43];Anterior segment optical coherence tomography [27, 49];Macular oedema [11, 17, 20, 21, 24, 25, 30];Outcome measures correlated to structural damage:Visual acuity [7–11, 13, 14, 17, 19–21, 23, 24, 30–33, 35, 36, 38–42, 45, 46, 48, 50–57];Development of structural complications [5, 7, 9–12, 17, 20, 22, 24–26, 28–33, 36–42, 45, 47, 48, 51–59];Surgery requirement [24, 29, 31, 34, 36, 39, 53, 55–57];Amblyopia [36];Outcome measures of severe disease course:Use and sparing of topical/oral corticosteroids [10, 13, 15, 18, 19, 21, 23–25, 28, 30, 32, 34–36, 38–41, 43, 44, 46, 51, 53, 54, 59];Biomarkers [27, 36–39, 47, 48, 59–66];Uveitis subtype [25, 50, 57];Bilateral disease [38, 39, 54–56];JIA persistence [38, 39];Quality of life assessments [27, 28, 35, 44, 67–69].Fig. 3Figurative presentations of the clustered measures of outcomes to assess uveitis Outcome measures to assess disease activity: Grade of cells in the anterior chamber [7–46];Grade of flare in the anterior chamber [7–18, 27, 36, 38, 39, 42, 43, 47, 48];Laser flare photometry [27, 33, 43];Anterior segment optical coherence tomography [27, 49];Macular oedema [11, 17, 20, 21, 24, 25, 30]; Outcome measures to assess disease activity: Grade of cells in the anterior chamber [7–46];Grade of flare in the anterior chamber [7–18, 27, 36, 38, 39, 42, 43, 47, 48];Laser flare photometry [27, 33, 43];Anterior segment optical coherence tomography [27, 49];Macular oedema [11, 17, 20, 21, 24, 25, 30]; Grade of cells in the anterior chamber [7–46]; Grade of cells in the anterior chamber [7–46]; Grade of flare in the anterior chamber [7–18, 27, 36, 38, 39, 42, 43, 47, 48]; Grade of flare in the anterior chamber [7–18, 27, 36, 38, 39, 42, 43, 47, 48]; Laser flare photometry [27, 33, 43]; Laser flare photometry [27, 33, 43]; Anterior segment optical coherence tomography [27, 49]; Anterior segment optical coherence tomography [27, 49]; Macular oedema [11, 17, 20, 21, 24, 25, 30]; Macular oedema [11, 17, 20, 21, 24, 25, 30]; Outcome measures correlated to structural damage:Visual acuity [7–11, 13, 14, 17, 19–21, 23, 24, 30–33, 35, 36, 38–42, 45, 46, 48, 50–57];Development of structural complications [5, 7, 9–12, 17, 20, 22, 24–26, 28–33, 36–42, 45, 47, 48, 51–59];Surgery requirement [24, 29, 31, 34, 36, 39, 53, 55–57];Amblyopia [36]; Outcome measures correlated to structural damage:Visual acuity [7–11, 13, 14, 17, 19–21, 23, 24, 30–33, 35, 36, 38–42, 45, 46, 48, 50–57];Development of structural complications [5, 7, 9–12, 17, 20, 22, 24–26, 28–33, 36–42, 45, 47, 48, 51–59];Surgery requirement [24, 29, 31, 34, 36, 39, 53, 55–57];Amblyopia [36]; Visual acuity [7–11, 13, 14, 17, 19–21, 23, 24, 30–33, 35, 36, 38–42, 45, 46, 48, 50–57]; Visual acuity [7–11, 13, 14, 17, 19–21, 23, 24, 30–33, 35, 36, 38–42, 45, 46, 48, 50–57]; Development of structural complications [5, 7, 9–12, 17, 20, 22, 24–26, 28–33, 36–42, 45, 47, 48, 51–59]; Development of structural complications [5, 7, 9–12, 17, 20, 22, 24–26, 28–33, 36–42, 45, 47, 48, 51–59]; Surgery requirement [24, 29, 31, 34, 36, 39, 53, 55–57]; Surgery requirement [24, 29, 31, 34, 36, 39, 53, 55–57]; Amblyopia [36]; Amblyopia [36]; Outcome measures of severe disease course:Use and sparing of topical/oral corticosteroids [10, 13, 15, 18, 19, 21, 23–25, 28, 30, 32, 34–36, 38–41, 43, 44, 46, 51, 53, 54, 59];Biomarkers [27, 36–39, 47, 48, 59–66];Uveitis subtype [25, 50, 57];Bilateral disease [38, 39, 54–56];JIA persistence [38, 39]; Outcome measures of severe disease course:Use and sparing of topical/oral corticosteroids [10, 13, 15, 18, 19, 21, 23–25, 28, 30, 32, 34–36, 38–41, 43, 44, 46, 51, 53, 54, 59];Biomarkers [27, 36–39, 47, 48, 59–66];Uveitis subtype [25, 50, 57];Bilateral disease [38, 39, 54–56];JIA persistence [38, 39]; Use and sparing of topical/oral corticosteroids [10, 13, 15, 18, 19, 21, 23–25, 28, 30, 32, 34–36, 38–41, 43, 44, 46, 51, 53, 54, 59]; Use and sparing of topical/oral corticosteroids [10, 13, 15, 18, 19, 21, 23–25, 28, 30, 32, 34–36, 38–41, 43, 44, 46, 51, 53, 54, 59]; Biomarkers [27, 36–39, 47, 48, 59–66]; Biomarkers [27, 36–39, 47, 48, 59–66]; Uveitis subtype [25, 50, 57]; Uveitis subtype [25, 50, 57]; Bilateral disease [38, 39, 54–56]; Bilateral disease [38, 39, 54–56]; JIA persistence [38, 39]; JIA persistence [38, 39]; Quality of life assessments [27, 28, 35, 44, 67–69]. Quality of life assessments [27, 28, 35, 44, 67–69]. Figurative presentations of the clustered measures of outcomes to assess uveitis Outcome measures to assess disease activity The outcome measures used to assess disease activity were: grade of cells in the anterior chamber (AC) (29 studies, 78.4%) [7–35], grade of flare in the AC (13 studies, 35.1%) [7–18, 27], laser flare photometry (3 studies, 8.1%) [27, 33, 43], anterior segment optical coherence tomography (2 studies, 5.4%) [27, 49] and macular oedema (7 studies, 18.9%) [11, 17, 20, 21, 24, 25, 30]. The grade of cells and flare in the AC was widely used to assess disease activity; they are direct consequences of inflammation and are graded according to the Standardization of Uveitis Nomenclature (SUN) classification [70, 71]. It has been demonstrated that AC cells greater than or equal to 1+ cells and AC flare > 1 at the time of initial presentation increase the risk of developing ocular complications [38, 39]. The evaluation of cells and flare in the AC is performed with the slit lamp examination, which is a subjective technique characterized by interobserver variability and not always so well tolerated by children due to the exposure to direct light in the eye. Nonetheless, it is the key technique used to assess ocular inflammation, even in clinical trials [35, 43, 44]. However, over the last years, new objective techniques have been developed: laser flare photometry (LFP) and anterior segment optical coherence tomography (AS-OCT). LFP is a quantitative, reliable and non-invasive method to assess intraocular inflammation, which showed a significant correlation with slit lamp examination performed by an expert ophthalmologist [33]. LFP has been used in the randomized clinical trial ADJUVITE to assess the ocular inflammation in response to treatment as a reliable technique [43]. AS-OCT was recently described as an instrument to evaluate different aspects of the anterior segment, including AC inflammation [27, 72, 73]. It showed a high correlation with slit lamp examination, and it seems to be superior to a clinical exam in identifying subclinical inflammation [72]. The use of AS-OCT to assess disease activity holds promise for monitoring treatment response and in clinical studies, particularly when minor changes are not detectable through a clinical exam [27]. Macular oedema (ME), defined as the presence of macular thickening with or without cyst formation, is the most significant cause of vision loss caused by uveitis, and is potentially reversible if timely treated. ME can be detected already during the initial stage of severe inflammatory disease and may also develop during the later course of the disease [74]. ME can be detected by optical coherence tomography (OCT), a non-invasive, fast and repeatable technique that provides the measurement of the severity of ME through the evaluation of central macular thickness (CMT). As a sign of disease activity, ME evolution can be used as a marker of response to treatment of the underlying inflammatory process. Indeed, several authors considered ME as an indicator of disease activity and, as a reliable indicator of treatment response, as described in the APTITUDE trial [11, 17, 20, 35]. Outcome measures correlated to structural damage The outcome measures correlated to structural damage were: visual acuity (21 studies, 56.8%) [7–11, 13, 14, 17, 19–21, 23, 24, 30–33, 35, 50–52], development of structural complications (20 studies, 54.1%) [7, 9–12, 17, 20, 22, 24–26, 28–33, 51, 52, 58] and surgery requirement (4 studies, 10.8%) [24, 29, 31, 34]. Visual acuity (VA), classified with the SUN criteria [70, 71], was used as an outcome measure in most of the studies (56.8%). VA should be considered a useful measurement of uveitis activity, as well as an important indicator of ocular damage, strongly related to the disease. According to the SUN Working Group, the primary visual acuity thresholds for reporting results in uveitis studies should include 6/15 or worse (20/50 or worse) and 6/60 or worse (20/200 or worse) [70, 71]. VA results need to be converted to the logarithm of the minimum angle of resolution (logMAR) units for analysis. VA was a secondary outcome measure in one of the RCTs selected [35]. The development of structural complications was frequently used by several authors as an outcome in JIA-U. Structural complications are caused by chronic intraocular inflammation [29] and reflect previous and current disease activity, along with the time of exposure to corticosteroid therapy. They include cataracts, band keratopathy, synechiae, macular oedema, epiretinal membrane formation, glaucoma and ocular hypotony. Patients with complications at presentation showed worse VA values [50]. As mentioned, it is still debated whether macular oedema should be considered as a marker of disease activity and/or a complication of ocular inflammation. Additional ocular complications, of note cataracts, glaucoma and high intraocular pressure, are frequently due to steroid treatment, rather than the disease activity as per se. Schnabel et al. considered these latter complications as secondary outcome measures in patients who received high-dose intravenous methylprednisolone [7]. Maccora et al. found a significant correlation between the grade of ocular inflammation, evaluated by LFP, and the presence of complications, primarily cataracts and posterior synechiae [33]. Surgeries requirement is an outcome measure correlated to structural damage, but even to the severity of disease. Cataracts and intraocular hypertension not responding to medical treatment often require surgical intervention to prevent amblyopia and further complications. However, these procedures are challenging due to the increased risk of postoperative complications associated with underlying inflammation and to the necessity of adjusting immunosuppressive therapy to prevent postoperative infections and need to be properly balanced in a multidisciplinary setting [29]. It was shown that surgery requirement was statistically associated with reduced visual acuity at the last follow-up [57]. Van Meerwijk et al. [58] identified the presence of anterior segment complications and an intraocular pressure (IOP) >21 mmHg during the first uveitis remission as main risk factors for glaucoma surgery in paediatric uveitis. Cheung et al. [34] demonstrated in their study that the earlier initiation of methotrexate within 6 months and possibly the addition of a biological within 18 months reduced the need for ophthalmic surgery. Outcome measures of severe disease course Use and sparing of topical/oral corticosteroids (15 studies, 40.5%) [10, 13, 15, 18, 19, 21, 23–25, 28, 30, 32, 34, 35, 51], biomarkers (4 studies, 10.8%) [27, 60–62], and uveitis subtype (2 studies, 5.4%) [25, 50] have been detected as outcome measures of severe disease course. The sparing of topical/oral corticosteroids, while maintaining no disease activity, was considered a primary outcome for successful disease control in almost half of the included studies (40.5%). In adults, successful corticosteroid sparing is achieved with a dosage of prednisone of 10 mg/day or less [70], while in children, there is no agreement on how it should be defined for an optimal outcome measure. However, the goal would be to stop the systemic and topical corticosteroids completely. A delayed start of immunosuppressive treatment was shown to be associated with a higher rate of complications and a more severe disease course. Cheung et al. [34] showed that early immunosuppressive therapy reduces the need for ophthalmic surgery: delay in methotrexate use beyond six months significantly increases the risk of surgery (p = 0.033). The main biomarker used to predict the occurrence of uveitis is represented by antinuclear antibody (ANA) in the context of JIA patients, primarily in the oligoarticular subtype. Its role as a predictor of a more severe course of the disease is not confirmed. Morelle et al., in a large cohort of 147 paediatric patients with different types of uveitis, found more complications in the ANA+ JIA group than in any other groups [60]. Several studies identified S100 proteins, cytokines and chemokines as biomarkers in aqueous humor (AqH) and serum, reflecting both systemic and ocular inflammation. However, AqH sampling is an invasive technique, not feasible in all children. The identification of biomarkers in tear fluid shows great potential as a liquid biopsy due to its non-invasive collection compared to AqH sampling [61, 62]. S100A12, IL-8, and sICAM-1 were found to be significantly increased in tears of children with active uveitis [61]. Pro-inflammatory serum proteins S100A8/A9 and S100A12 were found to be elevated in a cross-sectional study that compared children with JIA-U or chronic anterior uveitis to controls [75]. Moreover, in the same study, S100A8/A9 levels in the aqueous humor of clinically inactive uveitis patients were significantly higher than controls, suggesting a subclinical ocular inflammation undetected by the slit lamp. Angeles-Han et al. [62]’s study found that S100A12 levels in tears were significantly increased in active uveitis compared to inactive uveitis; interleukin (IL)-8 levels were shown to be higher in children before starting uveitis treatment compared to those receiving corticosteroids and methotrexate. In children with inactive uveitis on methotrexate, IL-8 levels were reduced. However, among those with inactive uveitis undergoing ocular surgery, IL-8 levels were elevated compared to the control groups [61]. Transthyretin (TTR) is shown to be significantly elevated in the aqueous humor of JIA-U patients, particularly in active uveitis, but is absent in their serum; this suggests that TTR originates intraocularly and may serve as a specific biomarker [27]. A proteomic-analysis-based study [62] found that the relatively higher levels of five proteins—A2M, APOA1, S100A9, HP, and TTR—consistently distinguish children with JIA-U from those without uveitis (JIA-no-U), regardless of arthritis activity and topical corticosteroid use. The SUN Working Group [70, 71] classifies uveitis subtypes as chronic anterior, the most common, acute anterior, recurrent anterior and panuveitis. It was previously described that the type of uveitis is significantly associated with complication development (p < 0.0001) and blindness (p = 0.0096) [57]. Two new studies addressing uveitis subtypes as outcomes of a severe disease course have been recently reported. Yalçındağ et al. [50] demonstrated the most favourable visual outcomes in anterior uveitis, whereas panuveitis exhibited the poorest prognosis. Janetos et al. [25] described that patients with panuveitis are more likely to experience treatment failure compared to those with anterior uveitis. Quality of life assessment Only 3 studies (8.1%) [27, 28, 35] included quality of life assessment as an indicator of outcome. Rodriguez-Smith et al. [27] used the Effects of Youngsters’ Eyesight on Quality of Life (EYE-Q), which is the only one validated paediatric questionnaire that assesses vision-related quality of life (VRQOL) and so the overall quality of life and the child’s visual functioning [67, 76]. Uveitis in Childhood Prospective National Cohort Study [28] is a protocol aimed to investigate the outcomes of childhood uveitis in the United Kingdom, and it describes the impact of disease course on the quality of life for both child and family. Quality of life, measured by the Child Health Questionnaire and Childhood Health Assessment Questionnaire, was considered a secondary outcome in the APTITUDE trial [35]. Discussion The assessment of outcome measures in JIA-U is widely heterogeneous, although the part of the SUN criteria [70, 71] is a validated tool for assessing uveitis activity in adults, the most effective set of measures for evaluating ocular inflammation in children remains uncertain [27]. Shared outcome measures are essential both for designing endpoints in clinical trials and for guiding treatment choices in clinical practice. In 2019, the MIWGUC working group made the first step in developing a comprehensive set of measures of disease activity, severity and damage in JIA-U4. The current study was designed as an update of the previous systematic review published in 20192. Rather than re-evaluating previously established concepts, our objective was to determine whether the rapidly evolving literature published over the subsequent 5 years introduced new outcome measures or modified the relative importance of existing ones. The review led to the identification of 15 outcome measures for the assessment of JIA-U. It is interesting to note that in the last 5 years, the number of published articles about outcome measures in JIA-U has increased, this is probably due to the emergence of new techniques and knowledge in this field and to the awareness of the urgent need for standardized outcome measures. One of the most relevant findings of this update is the remarkable stability of the original outcome framework. Despite major therapeutic advances and the increasing use of biologic agents during the last decade, the majority of outcome measures identified in 2019 remain central in contemporary studies. Indeed, as for Mastrangelo et al. [2], the most frequent outcome measures were the assessment of cells and flare in the AC, visual acuity, development of structural complications and the use and sparing of immunosuppressive therapies. In order to identify aggregate and as much as possible unidirectional domains, the detected outcome measures have been split into 4 different groups: (1) outcome measures to assess disease activity; (2) outcome measures correlated to structural damage; (3) outcome measures of severe disease course, and (4) Quality of life. The first one represents the key indicator used to assess the ocular inflammation and consequently disease activity using grading of cells and flare in the AC according to the SUN guidelines [70, 71]. One of the most important developments since 2019 is the increasing interest in objective quantification of ocular inflammation. In this group, we included LFP and AS-OCT as new ways to assess disease activity based on a literature review, as they can provide a non-invasive, accurate and objective method to assess intraocular inflammation. These technologies were absent from the 2019 review [2]; their appearance in recent studies reflects the increasing interest in objective imaging technologies capable of reducing inter-observer variability associated with slit-lamp examination and they may represent important candidates for incorporation into future composite outcome measures. Cause it directly reflects the underlying inflammatory state and is potentially reversible if timely treated, we included ME among the measures of disease activity, and not into the complications/structural damage domain [11, 17, 20]. The second group included measures correlated to structural damage, including not only the direct complications of inflammation or the persistent corticosteroid treatment, but also the surgical treatment and the visual acuity, strongly influenced by the ocular damage related to the disease. The third group includes measures that can be associated with a severe disease course, thus they might classify patients into risk-stratified subgroups. This might be extremely useful in identifying patients who need more aggressive treatment rather than the standard treatment. Although they could be considered as risk factors, it appears anyway that they cannot be neglected. Although in the 2019 review [2], amblyopia, bilateral disease and JIA persistence have been identified as potential outcome measures, the present update did not find any paper reporting them in support. New evidence regarding inflammatory biomarkers detectable in tears of JIA-U children, significantly correlated with disease activity, is currently available [61]. This might represent a future promising finding, even though their availability and reliability in clinical setting need to be confirmed in larger studies. The main RCTs in paediatric uveitis over the last years used as primary and/or secondary outcomes several outcome measures reported in this systematic review. Specifically, the APTITUDE trial [35], published in 2020, assessed the safety and efficacy of subcutaneous tocilizumab in children with JIA-U, refractory to methotrexate and TNF-inhibitors, using as primary outcome the treatment response, defined as a reduction/resolution in AC cell inflammation score, according to the SUN classification. Secondary outcomes were the corticosteroid use, topical and/or systemic, visual acuity assessment, and quality of life measures, assessed by the Child Health Questionnaire and Childhood Health Assessment Questionnaire. The SYCAMORE [44] trial assessed adalimumab in JIA-U, defining as primary endpoint the time to treatment failure, measured by the grade of AC cells under slit-lamp examination, and as secondary outcome measures the use of corticosteroids, the Childhood Health Assessment Questionnaire and Child Health Questionnaire. The ADJUVITE trial [43] used as primary outcome the treatment response, defined as a reduction in ocular inflammation, assessed by LFP, without worsening of cell counts or protein flare on slit-lamp examination, whilst secondary outcomes included adjustments in topical and systemic steroid therapy. It is important to note that all three trials considered ocular inflammation of the AC as the primary outcome measure according to SUN, and only one trial (ADJUVITE trial [43]) a novel technique as the LFP. All three considered as secondary outcomes the reduction of corticosteroids as a key measure of disease activity. Although the aim of this systematic literature review is not to present a composite score to assess disease activity, we identified several indicators that can be clustered to identify active inflammation, ocular damage, predictors of worse disease activity and quality of life. The present update provides contemporary evidence supporting the ongoing refinement of the MIWGUC core outcome set. In particular, objective imaging tools and emerging biomarkers may complement traditional clinical assessments in future consensus exercises. Whether these novel measures should be incorporated into routine clinical trials remains to be determined through prospective validation studies. Indeed, the results of this review have been the starting data to discuss suitable outcome measures at the 11th MIWGUC consensus meeting held on 01/25 in Barcelona, Spain. The outcome measures identified from this preparatory literature systematic review have been selected and then voted according to the nominal group technique to generate a proposal of core set measures to be used in a 12-month clinical trial for JIA-U. Few caveats hamper and edge the conclusions of this study. This systematic review surveys the broad heterogeneity of JIA-U outcome measures, even in RCTs. However, a core of 9 measures was reported consistently across time. The data regarding the novel techniques to assess disease activity, along with novel biomarkers, are still scarce; it is presumed that they will increase in the next few years, considering their promising role. An inherent limitation of this work is its deliberate methodological similarity to the 2019 review [2], which was necessary to allow a direct comparison of outcome measures across time. However, this approach enabled a direct longitudinal comparison between the two review periods and allowed the identification of evolving trends, emerging technologies, and shifts in outcome assessment priorities that would otherwise have been difficult to recognize. As the available outcome measures for JIA-U result extremely fair, our analysis did not attempt to judge the reliability of these measures, thus not including specific limitations and qualitative assessment for the selection procedure of the entered studies and their related outcome measures. The outcome measures were used individually and not reported as a composite score, which limits our ability to create a composite score like JADAS, a tool designed to evaluate disease activity in JIA patients, based on four components: the number of affected joints, global assessments by both the physician and the patient or parent, and the erythrocyte sedimentation rate, as inflammatory marker [77]. In conclusion, this study provides a five-year longitudinal update of the previous 2019 systematic review [2] on outcome measures in JIA-U. We confirmed that the spectrum of outcome measures in the literature is widely heterogeneous. While the core domains identified in the 2019 review [2] remain largely unchanged, emerging imaging modalities and biomarker-based approaches suggest a progressive evolution toward more objective and standardized assessment strategies. These findings support the robustness of the original MIWGUC framework while providing an updated evidence base for its future refinement. Moreover, we propose a categorization into 4 groups to better emphasize outcome measures to assess disease activity, which have a crucial role in routine clinical practice and in the definition of endpoints in clinical trials. The present outcome measures are individually reported in each selected study. Based on the current available data, the weighted reciprocal effect size of each outcome measure is not assessed, thus a composite score cannot be created at present. Testing a set of selected measures in a prospective and representative JIA-U cohort might be the first step to identify a reliable method aiming to measure in a standardized way such a challenging disease. Overall, further research is needed to establish sensitive, quantifiable, and reproducible measures that can be easily implemented in clinical practice.